DAM
TVTX icon

DLD Asset Management’s Travere Therapeutics TVTX Stock Holding History

DLD Asset Management’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-32,700
Closed -$793K – 222
2022
Q2 		$793K Buy
+32,700
New +$822K 0.06% 133

Other funds holding TVTX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

DLD Asset Management's TVTX Position: Q3 2022 in Review

DLD Asset Management sold out of Travere Therapeutics (TVTX) in Q3 2022, closing a stake of 15,000 shares — an estimated $363K sold.

DLD Asset Management first reported a position in TVTX in Q2 2022 and held it in 1 quarter. The position peaked at $363K in Q2 2022. 171 funds tracked by Wall St. Rank hold TVTX as of Q3 2022.

  • DLD Asset Management reported no remaining Travere Therapeutics position as of Q3 2022 after selling out during the quarter.
  • DLD Asset Management sold 15,000 Travere Therapeutics shares in Q3 2022, an estimated $363K.
  • DLD Asset Management first reported a position in Travere Therapeutics in Q2 2022 and held it in 1 quarter.
  • DLD Asset Management's Travere Therapeutics position peaked at $363K in Q2 2022.
  • 171 funds tracked by Wall St. Rank held Travere Therapeutics as of Q3 2022.

Based on DLD Asset Management's 13F filing for Q3 2022, filed 14 Nov 2022.